EA202192908A1 - Способы, относящиеся к туберкулезу - Google Patents

Способы, относящиеся к туберкулезу

Info

Publication number
EA202192908A1
EA202192908A1 EA202192908A EA202192908A EA202192908A1 EA 202192908 A1 EA202192908 A1 EA 202192908A1 EA 202192908 A EA202192908 A EA 202192908A EA 202192908 A EA202192908 A EA 202192908A EA 202192908 A1 EA202192908 A1 EA 202192908A1
Authority
EA
Eurasian Patent Office
Prior art keywords
subject
tuberculosis
infection
active
methods related
Prior art date
Application number
EA202192908A
Other languages
English (en)
Inventor
Бенджамин Свифт
Кэтрин Рис
Original Assignee
Пибиди Биотек Лимитед
Зе Юниверсити Оф Ноттингем
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пибиди Биотек Лимитед, Зе Юниверсити Оф Ноттингем filed Critical Пибиди Биотек Лимитед
Publication of EA202192908A1 publication Critical patent/EA202192908A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к способу диагностики заболевания туберкулезом (ТБ) у субъекта. Способ включает смешивание специфичного в отношении микобактерий бактериофага с образцом мононуклеарных клеток периферической крови (МКПК) от субъекта с последующим определением наличия или отсутствия последовательности ДНК микобактерии в ДНК, выделенной из смеси. Согласно настоящему изобретению предложен чувствительный и специфичный тест на наличие начальной стадии ТБ, т.е. асимптомной инфекции с высоким риском развития активного ТБ, или на наличие латентной туберкулезной инфекции (ЛТИ), т.е. асимптомной инфекции, которая маловероятно разовьется в активный туберкулез, у субъекта.
EA202192908A 2019-05-21 2020-03-05 Способы, относящиеся к туберкулезу EA202192908A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1907157.0A GB201907157D0 (en) 2019-05-21 2019-05-21 Methods
PCT/GB2020/050524 WO2020234555A1 (en) 2019-05-21 2020-03-05 Methods relating to tuberculosis

Publications (1)

Publication Number Publication Date
EA202192908A1 true EA202192908A1 (ru) 2022-03-23

Family

ID=67226285

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192908A EA202192908A1 (ru) 2019-05-21 2020-03-05 Способы, относящиеся к туберкулезу

Country Status (13)

Country Link
US (1) US20220243258A1 (ru)
JP (1) JP2022534370A (ru)
KR (1) KR20220024127A (ru)
CN (1) CN114072524A (ru)
AU (1) AU2020277711B2 (ru)
BR (1) BR112021023254A2 (ru)
CA (1) CA3141503A1 (ru)
EA (1) EA202192908A1 (ru)
GB (1) GB201907157D0 (ru)
MX (1) MX2021014201A (ru)
SG (1) SG11202112880QA (ru)
WO (1) WO2020234555A1 (ru)
ZA (1) ZA202109307B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024092165A1 (en) * 2022-10-26 2024-05-02 The Administrators Of The Tulane Educational Fund Systems and methods for the automated diagnosis of mycobacterial infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776341B2 (en) * 2006-08-10 2010-08-17 Colorado State University Research Foundation Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens
CA2758124A1 (en) * 2008-04-19 2009-10-22 New York University Immunodominant mycobacterium tuberculosis peptides from cell wall proteins for early diagnosis and immunization
US8658350B2 (en) * 2008-09-22 2014-02-25 Oregon Health & Science University Methods for detecting Mycobacterium tuberculosis disease
US8058022B2 (en) * 2009-07-27 2011-11-15 Indian Institute Of Science Diagnosis and monitoring of mycobacterium tuberculosis infection
GB201213567D0 (en) * 2012-07-31 2012-09-12 Proteinlogic Ltd Biomarkers
US10344339B2 (en) 2013-10-01 2019-07-09 The University Of Nottingham Mycobacteria detection using bacteriophages
GB201401603D0 (en) * 2014-01-30 2014-03-19 Proteinlogic Ltd Biomarkers

Also Published As

Publication number Publication date
KR20220024127A (ko) 2022-03-03
WO2020234555A1 (en) 2020-11-26
MX2021014201A (es) 2022-02-21
BR112021023254A2 (pt) 2022-02-08
JP2022534370A (ja) 2022-07-29
AU2020277711B2 (en) 2024-06-27
SG11202112880QA (en) 2021-12-30
EP3973078A1 (en) 2022-03-30
CA3141503A1 (en) 2020-11-26
US20220243258A1 (en) 2022-08-04
GB201907157D0 (en) 2019-07-03
ZA202109307B (en) 2023-04-26
AU2020277711A1 (en) 2022-01-06
CN114072524A (zh) 2022-02-18

Similar Documents

Publication Publication Date Title
Cattamanchi et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis
Biraro et al. The use of interferon gamma inducible protein 10 as a potential biomarker in the diagnosis of latent tuberculosis infection in Uganda
Lalvani et al. Interferon gamma release assays: principles and practice
Kellar et al. Multiple cytokines are released when blood from patients with tuberculosis is stimulated with Mycobacterium tuberculosis antigens
Parmigiani et al. Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation
Karam et al. Sensitivity of IFN-γ release assay to detect latent tuberculosis infection is retained in HIV-infected patients but dependent on HIV/AIDS progression
Sester et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states
Wang et al. Evaluation of the diagnostic potential of IP-10 and IL-2 as biomarkers for the diagnosis of active and latent tuberculosis in a BCG-vaccinated population
Kunnath-Velayudhan et al. Immunodiagnosis of tuberculosis: a dynamic view of biomarker discovery
Chegou et al. Potential of host markers produced by infection phase-dependent antigen-stimulated cells for the diagnosis of tuberculosis in a highly endemic area
Sun et al. Potential role for Mycobacterium tuberculosis specific IL-2 and IFN-γ responses in discriminating between latent infection and active disease after long-term stimulation
Labugger et al. Detection of transrenal DNA for the diagnosis of pulmonary tuberculosis and treatment monitoring
De Groote et al. Highly multiplexed proteomic analysis of quantiferon supernatants to identify biomarkers of latent tuberculosis infection
Sebina et al. Circulating B-lymphocytes as potential biomarkers of tuberculosis infection activity
Van Den Broucke et al. Clinical and microscopic predictors of Entamoeba histolytica intestinal infection in travelers and migrants diagnosed with Entamoeba histolytica/dispar infection
Verma-Kumar et al. Serodiagnosis of tuberculosis in Asian elephants (Elephas maximus) in Southern India: a latent class analysis
van Hooij et al. Prototype multi-biomarker test for point-of-care leprosy diagnostics
Gomes et al. Succinyl-CoA synthetase: new antigen candidate of Bartonella bacilliformis
Kondo et al. Comparative evaluation of the Geenius HIV 1/2 Confirmatory Assay and the HIV-1 and HIV-2 Western blots in the Japanese population
Fernández-González et al. Clinical performance of a standardized SARS-CoV-2 interferon-γ release assay for simple detection of T-cell responses after infection or vaccination
Gatechompol et al. Monocyte-to-lymphocyte ratio as a predictor of TB among people living with HIV
Chen et al. Cytokine and antibody based diagnostic algorithms for sputum culture-positive pulmonary tuberculosis
Bertholet et al. Effect of chemotherapy on whole-blood cytokine responses to Mycobacterium tuberculosis antigens in a small cohort of patients with pulmonary tuberculosis
Reddy et al. Detecting Mycobacterium tuberculosis using the loop-mediated isothermal amplification test in South Africa
EA202192908A1 (ru) Способы, относящиеся к туберкулезу